Amarin Stock Price, News & Analysis

Amarin (NASDAQ:AMRN) praised the FDA for updating fenofibrate labeling on Oct 27, 2025, to state a lack of cardiovascular benefit and to add safety language and a narrowed indication.

The label cites two large diabetes trials and PROMINENT, and warns of increased rhabdomyolysis risk when fibrates are combined with statins. The release notes >11 million US fibrate prescriptions in 2023, >60% co-prescribed with statins, and ~2 million fibrate patients in Western Europe.

Amarin said the change should shift prescribing toward FDA-approved, outcome-proven therapies such as VASCEPA (icosapent ethyl).

Amarin (NASDAQ: AMRN) will report third quarter 2025 financial results and host a conference call on Wednesday, October 29, 2025.

The company will release results in pre-market hours followed by a live call with senior management at 8:00 a.m. ET. Investors can join via telephone (US: 877-545-0523; International: 973-528-0016; Access Code: 459510) or via webcast on the Investor Relations website at www.amarincorp.com. A replay will be available by phone (US: 877-481-4010; International: 919-882-2331; Access Code: 53008) and online through the Investor Relations site beginning shortly after the call and available until March 29, 2026.

Amarin (NASDAQ: AMRN) and Canadian partner HLS Therapeutics will present new REDUCE-IT and EPA mechanistic data at the Canadian Cardiovascular Congress in Quebec City, Oct 23–26, 2025.

Multiple abstracts and posters—including ENCORE analyses of Icosapent Ethyl (IPE) clinical value, Lp(a) oxidation inhibition by EPA, EPA+GLP-1 receptor agonist endothelial effects, and hospitalization/death outcomes from REDUCE‑IT—are scheduled for Oct 24, 2025 (board/poster sessions at 5:30pm ET and an oral presentation at 6:00pm ET).

VASCEPA is commercialized in Canada via the HLS collaboration.

Amarin Corporation (NASDAQ:AMRN) presented new in vitro data at the European Society of Cardiology (ESC) Congress 2025 in Madrid, highlighting key mechanistic insights into VASCEPA®/VAZKEPA® (eicosapentaenoic acid/EPA).

The research revealed two significant findings: First, EPA demonstrated potential to reduce inflammation in atherosclerotic cardiovascular disease (ASCVD) by modulating the ATP-P2X7 axis and NLRP3 inflammasome activation in monocyte-derived macrophages. Second, EPA showed ability to inhibit lipoprotein(a) [Lp(a)] oxidation and attenuate its effects on oxidative stress and pro-inflammatory protein expression in endothelial cells.

These findings suggest that EPA's cardiovascular benefits may extend beyond its known triglyceride-lowering effects, potentially offering additional mechanisms for reducing cardiovascular risk in at-risk patients.

Amarin Corporation (NASDAQ:AMRN) presented three significant sub-analyses from the REDUCE-IT® trial at ESC Congress 2025, demonstrating the effectiveness of VASCEPA®/VAZKEPA® (icosapent ethyl) in reducing cardiovascular risks. Key findings showed that the treatment resulted in 9% fewer total hospitalizations and significant cardiovascular risk reductions across multiple patient subgroups.

The analyses revealed a 44% relative risk reduction in cardiovascular events for patients with CKM syndrome and eGFR <60. The treatment showed significant reductions in major adverse cardiovascular events across all quartiles of baseline ApoB and TRL-C concentrations. Additionally, the 2025 ESC/EAS Dyslipidemia Guideline Update reaffirmed icosapent ethyl as a Class IIA recommended therapy for high-risk or very high-risk patients.

Amarin Corporation (NASDAQ:AMRN) announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain, featuring new analyses from the REDUCE-IT trial and EPA mechanistic data. The presentations will focus on icosapent ethyl's (IPE) cardioprotective effects through multiple mechanisms.

The data will explore IPE's impact on inflammation, lipoprotein oxidation, cardiovascular risk associated with CV-kidney-metabolic (CKM) syndrome, and hospitalization risks. Key presentations include analyses of cardiovascular risk reduction across specific patient subtypes and mechanistic studies investigating EPA's effects on inflammasome activation and lipoprotein(a) oxidation.

The congress will feature both oral and moderated poster presentations, scheduled from August 29th to September 1st, 2025, demonstrating Amarin's commitment to advancing cardiovascular care science.

Amarin Corporation (NASDAQ:AMRN) reported Q2 2025 financial results, highlighting two major strategic initiatives: a partnership with Recordati for European VAZKEPA® commercialization and a global restructuring targeting $70 million in cost savings over 12 months.

Q2 2025 financial highlights include total net revenue of $72.7 million (up 8% YoY), with product revenue declining 2% to $46.6 million and licensing revenue increasing 31% to $26.1 million. The company reported a net loss of $14.1 million versus net income of $1.5 million in Q2 2024. Amarin maintains a strong balance sheet with $298.7 million in cash and no debt.

The Recordati partnership covers VAZKEPA commercialization across 59 European countries, with transition expected to complete by end of 2025. The restructuring primarily involves eliminating European commercial roles.

Amarin Corporation (NASDAQ:AMRN) has scheduled its second quarter 2025 financial results conference call for July 30, 2025, at 8:00 a.m. ET. The company will release its Q2 2025 financial results before market opening on the same day.

The conference call will feature President & CEO Aaron Berg and senior management discussing quarterly results and recent strategic initiatives, followed by a Q&A session. Investors can access the call through the company's website or via provided dial-in numbers, with replay options available afterward.

Amarin (NASDAQ:AMRN) has announced an exclusive license and supply agreement with Recordati to commercialize VAZKEPA® across 59 European countries. The deal includes a $25 million upfront payment and potential milestone payments up to $150 million based on sales performance.

As part of this strategic move, Amarin will streamline its global operations, targeting $70 million in cost savings over the next 12 months. The company maintains a strong financial position with nearly $300 million in cash and no debt. The agreement, which extends until 2039, includes supply-based revenues and royalties, positioning Amarin to accelerate its path to positive cash flow while maintaining multiple revenue streams.